Mammal Patents (Class 800/14)
-
Patent number: 7919672Abstract: The invention provides a novel approach to increase immunoglobulin expression in non-human transgenic animals. For instance, the invention provides a method to increase humanized immunoglobulin production in animals genetically engineered to express one or several human or humanized immunoglobulin transloci. This can be done by overexpressing the apoptosis inhibitor, i.e. a rabbit bcl-2, whose expression is driven by a B-cell specific promoter specifically in the B-cell of the animal, thereby enhancing the survival of B-cells. This invention further relates to a method for selectively enhancing the survival of exogenous B-cells, that is B-cells expressing any immunoglobulin transgene locus, over the survival of endogenous B-cells that do not express the transgene locus. Selectivity is achieved by expressing the apoptosis-inhibitor only within exogenous B-cells, that is, by coupling exogenous immunoglobulin expression with apoptosis inhibitor expression.Type: GrantFiled: August 2, 2006Date of Patent: April 5, 2011Assignee: Therapeutic Human Polyclonals, Inc.Inventors: Roland Buelow, Josef Platzer
-
Patent number: 7919674Abstract: It is an object of the present invention to provide a high affinity antibody effective as a diagnostic or therapeutic for various diseases; a transgenic mammal for producing the high affinity antibody; and a medicine comprising the high affinity antibody or a cell producing the high affinity antibody. According to the present invention, a transgenic mammal carrying a GANP gene transferred thereinto, its progeny, or a part thereof, and a method of producing a high affinity antibody using the same are provided.Type: GrantFiled: November 7, 2003Date of Patent: April 5, 2011Assignee: Immunokick IncorporationInventor: Nobuo Sakaguchi
-
Publication number: 20110076289Abstract: The present invention provides a transgenic animal model of Alzheimer's Disease designated TgCRND8 as well as a method for making such model, which allows for the characterization of the etiology of the disease as well as for provide a system for the development and testing of potential treatments.Type: ApplicationFiled: June 30, 2010Publication date: March 31, 2011Applicant: Governing Council of the University of TorontoInventors: Peter H. St. George-Hyslop, Paul E. Fraser, David Westaway
-
Publication number: 20110077208Abstract: The invention features a process of expressing secreted recombinant human alpha-fetoprotein (rHuAFP) in the milk or urine of transgenic mammals.Type: ApplicationFiled: May 28, 2010Publication date: March 31, 2011Applicant: Merrimack Pharmaceuticals, Inc.Inventors: Stace Lindsay, Robert Mulroy, Daniel Semeniuk
-
Publication number: 20110072527Abstract: Method of preparing I-CreI meganuclease variants having a modified cleavage specificity, variants obtainable by said method and their applications either for cleaving new DNA target or for genetic engineering and genome engineering for non-therapeutic purposes. Nucleic acids encoding said variants, expression cassettes comprising said nucleic acids, vectors comprising said expression cassettes, cells or organisms, plants or animals except humans, transformed by said vectors.Type: ApplicationFiled: August 20, 2010Publication date: March 24, 2011Applicant: CELLECTISInventors: Philippe DUCHATEAU, Frederic Paques
-
Publication number: 20110072524Abstract: The present invention relates, generally, to a transgenic non-human animal model of hemophilia A, wherein the transgenic animal is deficient in endogenous Factor VIII and endogenous von Willebrand Factor, and methods to treat hereditary or acquired hemophilia A or von Willebrand Disease (VWD) by administration of exogenous human VWF.Type: ApplicationFiled: August 4, 2010Publication date: March 24, 2011Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.Inventors: Peter Turecek, Raffi Udin Ahmad, Herbert Gritsch, Eva-Maria Muchitsch, Hans-Peter Schwarz
-
Publication number: 20110067122Abstract: The present invention relates to the production of a transgenic ungulate which comprises a genetic modification that results in inactivation and loss of expression of its endogenous antibodies, and the expression of xenogenous antibodies, preferably human antibodies. This is effected by inactivation of the IgM heavy chain expression and, optionally, by inactivation of the Ig light chain expression, and by the further introduction of an artificial chromosome which results in the expression of non-bovine antibodies, preferably human antibodies.Type: ApplicationFiled: February 9, 2009Publication date: March 17, 2011Applicant: Kyowa Hakko Kirin Co., Ltd.Inventors: James M. Robl, Richard A. Goldsby, Stacy E. Ferguson, Yoshimi Kuroiwa, Kazuma Tomizuka, Isao Ishida, Barbara A. Osborne
-
Publication number: 20110059510Abstract: The invention relates to transgenic rabbits that produce human factor VII in their mammary glands. The milk of said transgenic rabbits can be used as a raw material for the production of recombinant human factor VII.Type: ApplicationFiled: March 25, 2008Publication date: March 10, 2011Inventor: Pierre-Jean Ripoll
-
Publication number: 20110055938Abstract: A transgenic animal is provided. In certain embodiments, the transgenic animal comprises a genome comprising: an immunoglobulin light chain locus comprising: a) a functional immunoglobulin light chain gene comprising a transcribed variable region encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of 2 to 5 different amino acids; and ii. a light chain framework; and, operably linked to the functional immunoglobulin light chain gene: b) a plurality of pseudogene light chain variable regions each encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of the same 2 to 5 different amino acids as the CDRs of the functional gene; and ii. a light chain framework that is identical in amino acid sequence to the light chain framework of the transcribed variable region.Type: ApplicationFiled: August 11, 2010Publication date: March 3, 2011Inventors: WILLIAM DON HARRIMAN, ROBERT ETCHES, PHIL LEIGHTON
-
Publication number: 20110055940Abstract: The invention relates to mammalian PAI-I ligands and modulators. In particular, the invention relates to polypeptides, polypeptide compositions and polynucleotides that encode polypeptides that are ligands and/or modulators of PAI-I. The invention also relates to polyligands that are homopolyligands or heteropolyligands that modulate PAI-I activity. The invention also relates to ligands and polyligands localized to a region of a cell. The invention also relates to localization tethers and promoter sequences that can be used to provide spatial control of the PAI-I ligands and polyligands. The invention also relates to inducible gene switches that can be used to provide temporal control of the PAI-I ligands and polyligands. The invention also relates to methods of treating or preventing atherosclerosis. The invention also relates to methods of treating or preventing fibrosis.Type: ApplicationFiled: January 9, 2009Publication date: March 3, 2011Applicant: Intrexon CorporationInventors: Thomas D. Reed, Richard E. Peterson, Charles C. Reed, Joan Mazzarelli Sopczynski, Bethany L. Merenick, Jonathan Carson, Catherine L. Bair, Elena Tasheva
-
Publication number: 20110055936Abstract: Provided are non-human mammals comprising a transgenic nucleic acid sequence capable of causing an alteration of expression of Bri2 or Bri3 in the mammal. Also provided are non-human mammals comprising a Bri2 or Bri3 gene under the control of the native Bri2 or Bri3 promoter. Additionally provided are non-human mammals genetically engineered to lack expression of a Bri2 or Bri3 gene. Further, non-human mammals comprising a transgene encoding a Bri2 or Bri3 protein under the control of the ?CaMKII promoter are provided. Non-human mammals comprising a transgene encoding a furin protein are additionally provided. Embryonic stem cells of any of the above-described non-human mammals are further provided. Methods of screening a compound for treatment of a disease characterized by cerebral amyloidosis are additionally provided. Also provided are methods of making transgenic non-human mammals.Type: ApplicationFiled: November 20, 2007Publication date: March 3, 2011Inventors: Luciano D'Adamio, Luca Giliberto
-
Patent number: 7893316Abstract: The invention concerns the reconstruction in vitro of non-human mammal embryos by a method which consists in treating the nucleus of a somatic donor cell prior to its transfer into a receiver cytoplasm, said treatment comprising controlled proteolysis of non-histone proteins, and inducing an isomorphic swelling of said nucleus.Type: GrantFiled: September 29, 2000Date of Patent: February 22, 2011Assignee: Institut National de la Recherche Agronomique (INRA)Inventors: Jean-Paul Renard, Xavier Vignon
-
Publication number: 20110041192Abstract: Provided herein is a recombinant non-human mammal having an immune system including human immune cells and having a liver including human liver cells, and methods for producing the same. Also provided are methods of screening a compound for activity in treating hepatitis, comprising: administering a test compound to a recombinant non-human mammal as described herein; and then detecting the presence or absence of said activity in said mammal (e.g., by biochemical assay), said presence of said activity in said mammal indicating that said compound has activity in treating hepatitis. Methods of making fusion cells useful for the production of human monoclonal antibodies are also provided.Type: ApplicationFiled: February 20, 2009Publication date: February 17, 2011Inventors: Lishan Su, Liguo Zhang, Michael Washburn
-
Publication number: 20110041191Abstract: The present invention relates to a transgenic animal suitable for modelling Alzheimer's Disease. The present invention also relates to cells and gametes of the transgenic animal of the invention, along with nucleic acids and vectors suitable for generating the transgenic animal. Methods of generating the transgenic animal are also described, along with screening methods utilizing the transgenic animal.Type: ApplicationFiled: July 9, 2010Publication date: February 17, 2011Inventors: Bettina Platt, Gernot Riedel
-
Publication number: 20110035819Abstract: A synthetic hCFTR DNA sequence has been developed that produces remarkably high levels of hCFTR mRNA and protein in dosed murine lungs and human cells in culture compared to the natural hCFTR cDNA. This synthetic DNA addresses problems inherent in some natural cDNAs, such as premature transcriptional truncation sites introduced during cDNA synthesis. Introns are initially present in mRNA until the mRNA is processed. cDNA made from processed mRNA is devoid of introns. Thus DNA sequences (exon junctions) are present in a cDNA molecule which are not present in cells in nature. These exon junctions may affect transcription. Methods for improving expression of CFTR are based on sequence changes in cDNA molecules. The improvement methods may be applied to other cDNA molecules which are refractory to in vivo expression efforts. Compositions embodying the sequence changes increase the production of both transgenic mRNA and protein from cDNA molecules.Type: ApplicationFiled: October 12, 2007Publication date: February 10, 2011Applicant: COPERNICUS THERAPEUTICS INC.Inventors: Mark J. Cooper, Linas Padegimas
-
Publication number: 20110035816Abstract: The present invention provides a desired rat or a rat cell which contains a predefined, specific and desired alteration rendering the rat or rat cell predisposed to alterations in drug and chemical metabolism by modification of its structure or mechanism. Specifically, the invention pertains to a genetically altered rat, or a rat cell in culture, that is defective in at least one of two alleles of a drug metabolism gene such as the Cyp7b1 gene, the Cyp3a4 gene, etc. In another embodiment, the rat cell is a somatic cell. The inactivation of at least one drug metabolism allele results in an animal with a higher susceptibility to altered drug and chemical metabolism. In one embodiment, the genetically altered animal is a rat of this type and is able to serve as a useful model for altered drug and chemical metabolism or toxicology and as a test animal for autoimmune and other studies. The invention additionally pertains to the use of such rats or rat cells, and their progeny in research and medicine.Type: ApplicationFiled: August 5, 2010Publication date: February 10, 2011Inventors: Eric M. Ostertag, John Stuart Crawford
-
Publication number: 20110030072Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding immunodeficiency proteins. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of assessing the effects of agents in genetically modified animals and cells comprising edited chromosomal sequences encoding immunodeficiency proteins.Type: ApplicationFiled: July 23, 2010Publication date: February 3, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
-
Publication number: 20110030077Abstract: The present invention is directed to methods of modulating bile acid and lipid transport via the organic solute and steroid transporter Ost?-Ost?. The present invention is further directed to methods of treating a patient having dyslipidemia or a condition associated with altered bile acid homeostasis. Therapeutic agents and pharmaceutical compositions that modulate Ost?-Ost? heteromeric complex formation and/or transport activity are also disclosed.Type: ApplicationFiled: February 2, 2009Publication date: February 3, 2011Applicant: UNIVERSITY OF ROCHESTERInventors: Nazzareno Ballatori, Na Li
-
Publication number: 20110030078Abstract: The present invention is directed to a Trypanosome-resistant, non-human transgenic animal whose somatic and germ cells comprise a nucleic acid which encodes an apolipoprotein L-I polypeptide (apoL-I). The apoL-I protein has the amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5. The first nucleic acid transgene is operatively associated with at least one expression regulatory sequence. Methods of producing and raising such transgenic animals as well as transgenic eggs and sperm are also disclosed.Type: ApplicationFiled: August 2, 2010Publication date: February 3, 2011Applicant: NEW YORK UNIVERSITYInventors: Jayne RAPER, Russell THOMPSON, Marie SAMANOVIC, Maria Del Pilar Molina PORTELA
-
Publication number: 20110030076Abstract: Disclosed herein are methods and compositions for targeted cleavage of a genomic sequence, targeted alteration of a genomic sequence, and targeted recombination between a genomic region and an exogenous polynucleotide homologous to the genomic region. The compositions include fusion proteins comprising a cleavage domain (or cleavage half-domain) and an engineered zinc finger domain and polynucleotides encoding same. Methods for targeted cleavage include introduction of such fusion proteins, or polynucleotides encoding same, into a cell. Methods for targeted recombination additionally include introduction of an exogenous polynucleotide homologous to a genomic region into cells comprising the disclosed fusion proteins.Type: ApplicationFiled: July 16, 2010Publication date: February 3, 2011Inventors: Fyodor Urnov, Michael C. Holmes, Jeffrey C. Miller, Carl O. Pabo
-
Publication number: 20110023156Abstract: The present invention provides a genetically modified feline or cell comprising at least one edited chromosomal sequence. In particular, the chromosomal sequence is edited using a zinc finger nuclease-mediated editing process. The disclosure also provides zinc finger nucleases that target specific chromosomal sequences in the feline genome.Type: ApplicationFiled: July 23, 2010Publication date: January 27, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Joseph Bedell, Gregory Davis, Shondra Miller, Brian Buntaine, Xiaoxia Cui
-
Publication number: 20110023152Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins that are associated with cognitive disorders. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of assessing the effects of agents in genetically modified animals and cells comprising edited chromosomal sequences associated with cognitive disorders.Type: ApplicationFiled: July 23, 2010Publication date: January 27, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
-
Publication number: 20110023157Abstract: The present invention provides a genetically modified equine or cell comprising at least one edited chromosomal sequence. In particular, the chromosomal sequence is edited using a zinc finger nuclease-mediated editing process. The disclosure also provides zinc finger nucleases that target specific chromosomal sequences in the equine genome.Type: ApplicationFiled: July 23, 2010Publication date: January 27, 2011Applicant: Sigma-Aldrich Co.Inventors: Joseph Bedell, Brian Buntaine, Xiaoxia Cui
-
Publication number: 20110023146Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins that are associated with a secretase disorder. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of using the genetically modified animals or cells disclosed herein to screen agents for toxicity and other effects.Type: ApplicationFiled: July 23, 2010Publication date: January 27, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Phil Simmons, Xiaoxia Cui
-
Publication number: 20110023139Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal involved in cardiovascular disease. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. The invention also provides zinc finger nucleases that target chromosomal sequences involved in cardiovascular disease and the nucleic acids encoding said zinc finger nucleases. Also provided are methods of using the genetically modified animals or cells disclosed herein to screen agents for toxicity and other effects.Type: ApplicationFiled: July 23, 2010Publication date: January 27, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
-
Publication number: 20110023143Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins that are associated with neurodevelopmental disorders. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of using the genetically modified animals or cells disclosed herein to screen agents for toxicity and other effects.Type: ApplicationFiled: July 23, 2010Publication date: January 27, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
-
Publication number: 20110023153Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins associated with AD. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of using the genetically modified animals or cells disclosed herein to study AD development and methods of assessing the effects of agents in genetically modified animals and cells comprising edited chromosomal sequences encoding proteins associated with AD.Type: ApplicationFiled: July 23, 2010Publication date: January 27, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
-
Publication number: 20110023140Abstract: The present invention provides a genetically modified rabbit or cell comprising at least one edited chromosomal sequence. In particular, the chromosomal sequence is edited using a zinc finger nuclease-mediated editing process. The disclosure also provides zinc finger nucleases that target specific chromosomal sequences in the rabbit genome.Type: ApplicationFiled: July 23, 2010Publication date: January 27, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Joseph Bedell, Brian Buntaine, Xiaoxia Cui
-
Publication number: 20110023141Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins associated with Parkinson's disease. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of using the genetically modified animals or cells disclosed herein to study PD development and screen agents for assessing their effect on progression or symptoms of PD.Type: ApplicationFiled: July 23, 2010Publication date: January 27, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
-
Publication number: 20110023145Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins associated with ASD. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of using the genetically modified animals or cells disclosed herein to study ASD development and screen agents for assessing their effect on progression or symptoms of an ASD.Type: ApplicationFiled: July 23, 2010Publication date: January 27, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
-
Publication number: 20110023150Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences associated with schizophrenia. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. The invention also provides zinc finger nucleases that target chromosomal sequence associated with schizophrenia and the nucleic acids encoding said zinc finger nucleases. Also provided are methods of assessing the effects of agents in genetically modified animals and cells comprising edited chromosomal sequences associated with schizophrenia.Type: ApplicationFiled: July 23, 2010Publication date: January 27, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
-
Publication number: 20110023142Abstract: The present invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of gene(s) or gene product(s) resulting in cytokine-cytokine mediated autoimmune and inflammatory disease. In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human autoimmune and inflammatory disease and methods of their use. Specifically, the invention pertains to a genetically altered rat, or a rat cell in culture, that is defective in at least one of two alleles of a cytokine gene such as the Faslg gene, the Fas gene, etc. In one embodiment, the cytokine gene is the Faslg gene. In another embodiment, the cytokine gene is one of several known cytokine genes, such as Fas, IFN?, TNF-?, IL-2, IL-10, and IL-12.Type: ApplicationFiled: July 23, 2010Publication date: January 27, 2011Inventors: Eric M. Ostertag, John Stuart Crawford
-
Publication number: 20110023138Abstract: This invention relates to a mammalian artificial chromosome vector, which retains a human chromosome 7 fragment comprising human cytochrome P450 genes and is transmittable to progeny, wherein the human chromosome 7 fragment retains a region of approximately 1 Mb±500 Kb in size comprising at least a human CYP3A gene cluster, which region is located between chromosome markers AC004922 and AC073842, and to a non-human mammalian animal retaining the vector.Type: ApplicationFiled: October 14, 2008Publication date: January 27, 2011Applicants: National University Corporation Tottori University, Chromocenter Inc.Inventors: Mitsuo Oshimura, Yasuhiro Kazuki, Takashi Matsuoka, Kazuma Tomizuka, Takeshi Oshima
-
Publication number: 20110023147Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins that are associated with cognitive disorders. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of using the genetically modified animals or cells disclosed herein to screen agents for toxicity and other effects.Type: ApplicationFiled: July 23, 2010Publication date: January 27, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Phil Simmons, Xiaoxia Cui
-
Publication number: 20110023149Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences involved in tumor suppression. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. The invention also provides zinc finger nucleases that target chromosomal sequence involved in tumor suppression and the nucleic acids encoding the zinc finger nucleases. Also provided are methods of assessing the effects of agents in genetically modified animals and cells comprising edited chromosomal sequences involved in tumor suppression.Type: ApplicationFiled: July 23, 2010Publication date: January 27, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
-
Publication number: 20110023148Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins associated with addiction disorders. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. The invention also provides zinc finger nucleases that target chromosomal sequence encoding addiction-related proteins and the nucleic acids encoding said zinc finger nucleases. Also provided are methods of using the genetically modified animals or cells disclosed herein to screen agents for addiction and withdrawal side effects and other effects.Type: ApplicationFiled: July 23, 2010Publication date: January 27, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
-
Publication number: 20110023151Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding ABC transporter proteins. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of assessing the effects of agents in genetically modified animals and cells comprising edited chromosomal sequences encoding ABC transporter proteins.Type: ApplicationFiled: July 23, 2010Publication date: January 27, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
-
Publication number: 20110023136Abstract: A trifusion reporter plasmid is described that comprises a plasmid operably coupled to a mammalian FGF1B promoter that is operably coupled to a bioluminescence gene fused to a fluorescence gene fused to a nuclear medical imaging gene. The new reporter allows in vivo or ex vivo detection of gene expression in three different ways, in addition to traditional in vitro detection methods. Transgenic animals containing this new trifusion reporter and uses of same are described.Type: ApplicationFiled: July 24, 2009Publication date: January 27, 2011Applicant: National Health Research InstitutesInventors: Kurt M. Lin, Ing-Ming Chiu
-
Publication number: 20110016542Abstract: The present invention provides a genetically modified canine or cell comprising at least one edited chromosomal sequence. In particular, the chromosomal sequence is edited using a zinc finger nuclease-mediated editing process. The disclosure also provides zinc finger nucleases that target specific chromosomal sequences in the canine genome.Type: ApplicationFiled: July 23, 2010Publication date: January 20, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Joseph Bedell, Brian Buntaine, Xiaoxia Cui
-
Publication number: 20110016539Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins that are associated with neurotransmission disorders. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of using the genetically modified animals or cells disclosed herein to screen agents for toxicity and other effects.Type: ApplicationFiled: July 23, 2010Publication date: January 20, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
-
Publication number: 20110016543Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding inflammation-related proteins. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of assessing the effects of agents in genetically modified animals and cells comprising edited chromosomal sequences encoding inflammation-related proteins.Type: ApplicationFiled: July 23, 2010Publication date: January 20, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
-
Publication number: 20110016544Abstract: The invention discloses multiple genes related to age-related macular degeneration (AMD) and/or phagocytosis by RPE cells of the eye, and methods and compositions for detecting and treating AMD and other retinal degenerative conditions based on these phagocytosis-related and/or AMD-related genes. Also provided are animal models useful for testing therapeutic compounds and treatment protocols for AMD, and gene arrays including polymorphic variants of phagocytosis-related and/or AMD-related genes, useful for genetic screening of nucleic acid samples from subjects to obtain profiles of polymorphic variant sequences in a plurality of genes associated with AMD.Type: ApplicationFiled: August 13, 2009Publication date: January 20, 2011Inventors: George Inana, Margaret J. McLaren
-
Publication number: 20110016541Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins that are associated with nociception or taste disorders. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of using the genetically modified animals or cells disclosed herein to screen agents for toxicity and other effects.Type: ApplicationFiled: July 23, 2010Publication date: January 20, 2011Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
-
Publication number: 20110016547Abstract: The present invention relates to the use of regulatory sequences for mediating specific, early transient expression in proliverative neuronal determined cells. Furthermore, the uses of recombinant nucleic acid molecules comprising said defined regulatory sequences for mediating specific, early transient expression in proliverative neuronal determined cells as well as for the generation of non-human transgenic organisms and/or host cells are disclosed. In addition, the invention provides for transgenic non-human animals and/or host cells comprising said regulatory sequences and/or recombinant nucleic acid molecules. The invention also describes methods for the preparation of such vectors, host cells and transgenic non-human animals as well as methods for the detection and/or isolation of neuronal determined cells.Type: ApplicationFiled: September 30, 2010Publication date: January 20, 2011Inventors: Sébastien Couillard-Despres, Claudia Karl, Hans-Georg Kuhn, Ludwig Aigner
-
Publication number: 20110016545Abstract: The invention relates to enzymes having xylanase, mannanase and/or glucanase activity, e.g., catalyzing hydrolysis of internal ?-1,4-xylosidic linkages or endo-?-1,4-glucanase linkages; and/or degrading a linear polysaccharide beta-1,4-xylan into xylose. Thus, the invention provides methods and processes for breaking down hemicellulose, which is a major component of the cell wall of plants, including methods and processes for hydrolyzing hemicelluloses in any plant or wood or wood product, wood waste, paper pulp, paper product or paper waste or byproduct. In addition, methods of designing new xylanases, mannanases and/or glucanases and methods of use thereof are also provided. The xylanases, mannanases and/or glucanases have increased activity and stability at increased pH and temperature.Type: ApplicationFiled: August 1, 2008Publication date: January 20, 2011Applicant: VERENIUM CORPORATIONInventors: Kevin Gray, Reinhard Dirmeier
-
Publication number: 20110010785Abstract: The patent refers to a screening method carried out on biological material isolated from human and/or animal organisms for determining the risk of human and/or animal pathologies expressing an anomalous deposition of ?-amyloid and/or amyloid-like substance in human and/or animal organs and tissues, based on the investigation of the punctiform mutation Ala>Val in position 2 of the ?-protein (corresponding to the Ala673Val mutation precursor of the ?-protein containing 770 amino acids) in homozygosis or in heterozygosis. The patent provides for the possibility of: (1) creating unicellular or multicellular transgenic organisms expressing the Ala673Val mutation; (2) synthesising or producing peptides with such mutation and/or their derivatives and/or nucleic acids containing the same mutation; (3) using such products for studying the pathogenesis of the pathologies characterised by anomalous deposition of ?-amyloid and/or amyloid substance and for the prevention, diagnosis and care of such diseases.Type: ApplicationFiled: October 10, 2008Publication date: January 13, 2011Applicant: Fondazione I.R.C.C.S Istituto Neurologico "Carlo Besta"Inventors: Giuseppe DiFede, Michela Morbin, Fabrizio Tagliavini, Alfredo Martini
-
Publication number: 20110010786Abstract: The invention relates to a non-human transgenic mammal containing in its genome a DNA construct expressing a B cell antigen receptor specific for factor VIII of the coagulation pathway.Type: ApplicationFiled: July 9, 2010Publication date: January 13, 2011Inventor: Jean-Marie Saint-Remy
-
Patent number: 7868223Abstract: The present invention relates to a method for producing a modified foreign chromosome(s) or a fragment(s) thereof, which comprises the steps of: (a) preparing a microcell comprising a foreign chromosome(s) or a fragment(s) thereof, and transferring said foreign chromosome(s) or a fragment(s) into a cell with high homologous recombination efficiency through its fusion with said microcell; (b) in said cell with high homologous recombination efficiency, inserting a targeting vector by homologous recombination into a desired site of said foreign chromosome(s) or a fragment(s) thereof, and/or a desired site of a chromosome(s) derived from said cell with high homologous recombination efficiency, thereby marking said desired site; and (c) in said cell with high homologous recombination efficiency, causing deletion and/or translocation to occur at the marked site of said foreign chromosome(s) or a fragment(s) thereof.Type: GrantFiled: May 7, 2008Date of Patent: January 11, 2011Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Kazuma Tomizuka, Hitoshi Yoshida, Kazunori Hanaoka, Mitsuo Oshimura, Isao Ishida, Yoshimi Kuroiwa
-
Publication number: 20100333216Abstract: It is an object of the present invention to provide a non-human gene-disrupted animal with a disrupted ADAM11 gene. According to the present invention, a non-human gene-disrupted animal, wherein either one of or both alleles of an ADAM11 gene are disrupted, is provided.Type: ApplicationFiled: July 12, 2006Publication date: December 30, 2010Applicant: EISAI R&D MANAGEMENT CO., LTDInventors: Koji Sagane, Eiki Takahashi, Kazuto Yamazaki, Turo Oki
-
Publication number: 20100333218Abstract: A non-human transgenic mammalian animal, as described above, contains one or more exogenous double stranded DNA sequence(s) stably integrated into the genome of the animal, which comprises trans-acting regulatory units controlling expression of DNA sequences encoding proteins to be secreted into the milk of transgenic mammals. The DNA sequence of the trans-regulatory gene encodes transcriptional activating proteins, which are not secreted but made in a temporally controlled and mammary tissue specific manner. The DNA sequence containing the protein to be secreted in the milk is constructed on a separate gene sequence under the regulation of a minimal promoter and a trans-activation binding domain. The transgenic mammals are preferably pigs, cows, sheep, goats and rabbits. A related composition and method for making transgenic proteins which require specialized propeptides for proper post-translational processing is also described.Type: ApplicationFiled: May 24, 2010Publication date: December 30, 2010Applicant: PROGENETICS LLCInventors: Julian D. Cooper, Tanya K. O'Sickey, Stephen P. Butler